“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
KCCure joined with twelve other kidney cancer advocacy organizations urging Congress to double kidney cancer research funding for the Kidney Cancer Research Program (KCRP) administered by the Congressionally Directed Medical Research Program (CDMRP).
Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
At KCCure, Kidney Cancer Awareness month is about bringing patients, caregivers, researchers and doctors together to make our collective voice loud and clear. Help us tell the world that this disease exists, that we're fighting and that we need a cure!
The Kidney Cancer Research Alliance (KCCure) announced today the formation of a national kidney cancer Patient Advisory Board; a non-voting body made up of patients, caregivers and leaders in the cancer community. The board will be led by patient advocates Michael B. Lawing and Debra Gottsleben.
WASHINGTON - Kidney Cancer Research Alliance (KCCure) President Dena Battle has been elected to the National Cancer Institute’s Renal Task Force to serve as one of two patient advocates on the panel.
New data from the pivotal phase 3 Checkmate 214 trial combining ipilumimab and nivolumab presented at the European Society of Medical Oncology (ESMO) conference in Madrid showed superiority for the combination over Sunitinib (Sutent). This data will likely mean that the IO combination will move to approval for first line stage 4 RCC therapy.
The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures.
For our part, in honor of World Kidney Cancer Day – we are proud to announce that our first grant of $100,000 is being awarded to Dr. Wayne Marasco at Dana Farber Cancer Center for his continuing efforts to translate CAR T-Cell Therapy into a new treatment for kidney cancer.
As members of the International Kidney Cancer Coalition (IKCC), KCCure is a proud partner and participant of the first-ever World Kidney Cancer Q&A Day. On June 22, 2017, patients, caregivers, health care professionals and local organizations from around the world will join together to raise awareness about kidney cancer.